Medifast, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Medifast sells health and wellness products and services through its OPTAVIA brand and independent Coaches.
Financial results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $174.7 million | $349.0 million | Down 49.9% |
| Gross profit / gross margin | $127.3 million / 72.8% | $246.4 million / 70.6% | Profit down 48.3%; margin up 2.2 percentage points |
| SG&A / percentage of revenue | $119.4 million / 68.3% | $192.9 million / 55.3% | Expense down 38.1%; revenue share increased |
| Operating income / margin | $7.9 million / 4.5% | $53.5 million / 15.3% | Income down 85.2% |
| Net income | $8.3 million | $40.0 million | Down 79.2% |
| Diluted EPS | $0.76 | $3.67 | Down $2.91 |
| Operating cash flow | $7.3 million | $64.1 million | Down $56.8 million |
- Revenue pressure reflected fewer active earning Coaches (37,800 versus 58,700), lower revenue per active Coach ($4,623 versus $5,945), continued difficulty acquiring customers, and a $9.1 million prior-year timing benefit from changed sales-order terms.
- Gross margin improved through inventory-management efficiencies and Fuel for the Future cost savings, partly offset by higher shipping costs. SG&A fell with lower Coach compensation and sales volume, but declined less than revenue, reflecting fixed-cost deleverage and investment in customer acquisition and medically supported weight loss.
- Cash and cash equivalents were $97.5 million; investments were $59.0 million. Combined cash and investments totaled $156.4 million, versus $150.0 million at December 31, 2023. Working capital was $142.4 million.
- Total liabilities were $91.8 million, including $20.6 million of lease obligations. The company had no revolver borrowings or letters of credit outstanding and reported compliance with debt covenants. Its revolving facility provides $225 million of capacity, with up to $100 million of additional uncommitted capacity.
- Operating cash flow decreased substantially year over year. Inventory reductions provided $8.3 million of operating cash; accounts payable and accrued expenses used $15.9 million. Investing activities used $2.8 million and financing activities used $1.5 million. Q1 2024 dividends declared per share were zero, compared with $1.65 in Q1 2023.
Strategy, outlook and risks
- Medifast is expanding beyond its traditional Coach-led weight-management model, including product and service offerings for customers using GLP-1 medications. A LifeMD collaboration is intended to combine OPTAVIA coaching and nutrition support with access to affiliated clinicians and medication-related services.
- The company expected to begin an interim integrated lifestyle offering in Q2 2024 and planned a national marketing campaign and digital-experience upgrades. These are strategic plans, not quantified financial guidance; the filing provides no formal revenue or earnings forecast.
- Management cited GLP-1 medications and competitive pressure as challenges to customer acquisition, alongside inflation, consumer-spending uncertainty, and potential commodity, food, and supply-chain cost increases. The filing says the company may use pricing actions and adjust operations in response.
- LifeMD-related items affected results: Medifast recorded a $2.4 million unrealized gain on its LifeMD equity investment in other income and $1.3 million of collaboration service costs in SG&A. Its non-GAAP presentation excludes LifeMD-related amounts; adjusted net income was $7.2 million, or $0.66 per diluted share, versus GAAP net income of $8.3 million, or $0.76 per share. A further $1.2 million of prepaid services was expected to be expensed in Q2, and a final $2.5 million milestone payment was expected in Q2 as services are rendered.
- Ordinary-course litigation was not considered likely to have a material adverse effect, though outcomes cannot be predicted. The company reported no material changes to its previously disclosed risk factors and said disclosure controls were effective.
Investor verification priorities
- Track Coach count, Coach productivity, and customer-acquisition trends to assess whether the steep sales decline is stabilizing.
- Check whether the LifeMD offering, marketing campaign, and digital investments produce measurable customer growth and sustainable returns.
- Monitor gross-margin gains against higher shipping and other costs, and whether SG&A can be brought into line with lower revenue.
- Review operating cash generation, investment values—including the LifeMD equity position—and the timing and accounting of remaining collaboration costs.
- Confirm the absence of revolver borrowing and continued compliance with facility covenants, while considering the company’s lease obligations.